MA50495A - Composés bicycliques à fusion 5,6 et compositions pour le traitement de maladies parasitaires - Google Patents

Composés bicycliques à fusion 5,6 et compositions pour le traitement de maladies parasitaires

Info

Publication number
MA50495A
MA50495A MA050495A MA50495A MA50495A MA 50495 A MA50495 A MA 50495A MA 050495 A MA050495 A MA 050495A MA 50495 A MA50495 A MA 50495A MA 50495 A MA50495 A MA 50495A
Authority
MA
Morocco
Prior art keywords
compositions
treatment
parasitic diseases
fusion compounds
bicyclic
Prior art date
Application number
MA050495A
Other languages
English (en)
Inventor
Jan Jiricek
Isabelle K Lerario
Fang Liang
Xiaodong Liu
Valentina Molteni
Advait Suresh Nagle
Shuyi Pearly Ng
Maxim Ratnikov
Jeffrey M Smith
Yongping Xie
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA50495A publication Critical patent/MA50495A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/417Imidazole-alkylamines, e.g. histamine, phentolamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541Non-condensed thiazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA050495A 2017-05-31 2018-05-29 Composés bicycliques à fusion 5,6 et compositions pour le traitement de maladies parasitaires MA50495A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762513211P 2017-05-31 2017-05-31
US201762581919P 2017-11-06 2017-11-06

Publications (1)

Publication Number Publication Date
MA50495A true MA50495A (fr) 2021-04-28

Family

ID=62749123

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050495A MA50495A (fr) 2017-05-31 2018-05-29 Composés bicycliques à fusion 5,6 et compositions pour le traitement de maladies parasitaires

Country Status (26)

Country Link
US (2) US11384078B2 (fr)
EP (1) EP3630771B1 (fr)
JP (1) JP7187490B2 (fr)
KR (1) KR20200010275A (fr)
CN (1) CN110678468B (fr)
AR (1) AR111826A1 (fr)
AU (1) AU2018276190B2 (fr)
BR (1) BR112019024804A2 (fr)
CA (1) CA3060990A1 (fr)
CL (1) CL2019003467A1 (fr)
CO (1) CO2019013254A2 (fr)
CR (1) CR20190545A (fr)
CU (1) CU24543B1 (fr)
DO (1) DOP2019000299A (fr)
EC (1) ECSP19084722A (fr)
ES (1) ES2927207T3 (fr)
IL (1) IL270927B (fr)
JO (1) JOP20190278A1 (fr)
MA (1) MA50495A (fr)
MX (1) MX2019014321A (fr)
PE (1) PE20201148A1 (fr)
PH (1) PH12019502652A1 (fr)
RU (1) RU2738647C1 (fr)
TW (1) TW201902894A (fr)
UY (1) UY37745A (fr)
WO (1) WO2018220531A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190278A1 (ar) * 2017-05-31 2019-11-28 Novartis Ag مركبات 5، 6-ثنائية الحلقة مندمجة وتركيبات لعلاج الأمراض الطفيلية
US20230250064A1 (en) * 2020-06-23 2023-08-10 Shanghai Meiyue Biotech Development Co., Ltd. Preparation method for fused pyrazole-type compound

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10053275A1 (de) * 2000-10-27 2002-05-02 Dresden Arzneimittel Neue 7-Azaindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung
US7468376B2 (en) 2003-02-27 2008-12-23 Palau Pharma, S.A. Pyrazolopyridine derivates
BR102012004142A2 (pt) 2011-02-25 2015-04-07 Dow Agrosciences Llc Composições pesticidas e processos relacionados às mesmas
WO2013067302A1 (fr) * 2011-11-04 2013-05-10 Glaxosmithkline Intellectual Property (No. 2) Limited Méthode de traitement
WO2013106254A1 (fr) * 2012-01-11 2013-07-18 Dow Agrosciences Llc Compositions pesticides et procédés qui leur sont associés
JP6298472B2 (ja) 2012-11-19 2018-03-20 ノバルティス アーゲー 寄生虫病の処置のための化合物および組成物
UY35400A (es) * 2013-03-15 2014-10-31 Novartis Ag Compuestos y composiciones para el tratamiento de enfermedades parasitarias
US9186361B2 (en) * 2013-03-15 2015-11-17 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
PT3083627T (pt) * 2013-12-19 2018-11-30 Novartis Ag Derivados de[1,2,4]triazolo[1,5-a]pirimidina como inibidores do proteassoma em protozoários para o tratamento de doenças parasitárias como leishmaniose
BR112017011669A2 (pt) 2014-12-02 2018-02-27 Bayer Cropscience Aktiengesellschaft compostos bicíclicos como agentes de controle de pragas.
CN112679467A (zh) 2015-03-11 2021-04-20 Fmc公司 杂环取代的二环唑杀有害生物剂
TW201713661A (zh) * 2015-05-29 2017-04-16 葛蘭素史克智慧財產發展有限公司 化合物
DK3331885T3 (da) * 2015-08-07 2021-01-18 Glaxosmithkline Ip Dev Ltd Forbindelser
AU2017260125B2 (en) * 2016-05-03 2020-12-24 Bayer Pharma Aktiengesellschaft Aromatic sulfonamide derivatives
JOP20190278A1 (ar) * 2017-05-31 2019-11-28 Novartis Ag مركبات 5، 6-ثنائية الحلقة مندمجة وتركيبات لعلاج الأمراض الطفيلية

Also Published As

Publication number Publication date
PE20201148A1 (es) 2020-10-26
IL270927A (en) 2020-01-30
CN110678468B (zh) 2022-07-29
CL2019003467A1 (es) 2020-03-13
RU2738647C1 (ru) 2020-12-15
BR112019024804A2 (pt) 2020-06-09
AU2018276190A1 (en) 2019-11-07
DOP2019000299A (es) 2019-12-15
KR20200010275A (ko) 2020-01-30
PH12019502652A1 (en) 2020-07-13
CO2019013254A2 (es) 2020-01-17
JP7187490B2 (ja) 2022-12-12
CN110678468A (zh) 2020-01-10
AU2018276190B2 (en) 2020-05-14
AR111826A1 (es) 2019-08-21
CA3060990A1 (fr) 2018-12-06
UY37745A (es) 2019-01-02
JOP20190278A1 (ar) 2019-11-28
US20200109142A1 (en) 2020-04-09
CR20190545A (es) 2020-01-15
MX2019014321A (es) 2020-02-05
EP3630771A1 (fr) 2020-04-08
EP3630771B1 (fr) 2022-06-29
ECSP19084722A (es) 2019-12-27
CU24543B1 (es) 2021-08-06
ES2927207T3 (es) 2022-11-03
IL270927B (en) 2022-01-01
US20220324863A1 (en) 2022-10-13
US11384078B2 (en) 2022-07-12
CU20190095A7 (es) 2020-10-20
JP2020521775A (ja) 2020-07-27
WO2018220531A1 (fr) 2018-12-06
TW201902894A (zh) 2019-01-16

Similar Documents

Publication Publication Date Title
MA51200A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
MA55974A (fr) Composés triaryles pour le traitement de maladies pd-l1
MA55325A (fr) Composés pour le traitement de maladies pd-l1
MA49767A (fr) Conjugués de cytokine pour le traitement de maladies auto-immunes
MA51673A (fr) Composés destinés au traitement de troubles dépendant de la kinase
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
MA49279A (fr) Compositions d'anticorps optimisées pour le traitement de troubles oculaires
MX2018013472A (es) Tratamiento de combinacion de trastornos y enfermedades inflamatorios oculares.
MA46228A (fr) Inhibiteurs bicycliques fusionnés de l'interaction ménine-mll
MA53835A (fr) Lactams bicycliques en tant qu'inhibiteurs de la protéine kinase 1 interagissant avec des récepteurs pour le traitment p.e. de maladies inflammatoires
MA51916A (fr) Compositions pour le traitement de la dégénérescence maculaire liée à l'âge humide
MA44083A (fr) Composés de biarylmonobactame pour le traitement d'infections bactériennes
MA54229A (fr) Composés et compositions destinés au traitement d'états pathologiques associés à une activité de nlrp
MA47719A (fr) Esketamine pour le traitement de la dépression
MA45089A (fr) Utilisation d'indazoles 2-substitués pour le traitement et la prophylaxie de maladies auto-immunes
MA42953A (fr) Composés et compositions pour le traitement de troubles oculaires
MA44875A (fr) Compositions pour le traitement de troubles acido-basiques
MA54515A (fr) Dérivés de quinoléine destinés à être utilisés dans le traitement de maladies inflammatoires
WO2018067520A3 (fr) Procédés et agents thérapeutiques
MA51738A (fr) Composés pour le traitement de la douleur
DK3720433T3 (da) Bis-cholin-tetrathiomolybdat til behandling af wilsons sygdom
MA52873A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
MA46099A (fr) Composés pour le traitement de maladies associées à un dysfonctionnement mitochondrial
MA51672A (fr) Composés destinés au traitement des troubles kinases-dépendants
MA55148A (fr) Composés d'aryl-aniline et d'hétéroaryl-aniline pour le traitement de marques de naissance